Abstract
Introduction
Priapism is defined as persisting (>4 h), painful and abnormal tumescence that can occur without sexual stimulation. Three subtypes priapisms are seen—the non-ischemic priapism, intermittent and the ischemic priapism. In ischemic priapism, there is an abnormality in the veno-occlusive mechanism, resulting in venous stasis and accumulation of deoxygenated blood within the penile cavernosal tissue. Cavernosal tissue necrosis develops after extended period of ischemia and is eventually replaced by fibrotic tissue. It may results in erectile dysfunction if not treated promptly. Although, standard treatment of the ischemic priapism is penile aspiration and intracavernosal alpha-adrenergic agents, new oral agents have been investigated to reduce the cavernosal damage. In this study, the effect of different doses of pentoxifylline on cavernosal tissues was evaluated.
Materials and methods
Thirty-six male Wistar albino rats, age 5.5–6 months and weighing 250–300 g, were used in this study. The rats were randomly divided into five groups. In Group 1 (n = 7), the control group, only penectomy was performed. In Group 2 (n = 8), after 1 h of ischemic priapism, penectomy was performed. Group 3 (n = 7) received daily a 10 mg oral pentoxifylline for 4 weeks after 1 h of ischemic priapism, group 4 (n = 7) received a daily 30 mg oral pentoxifylline for 4 weeks after 1 h of ischemic priapism, and group 5 (n = 7) received a daily 100 mg oral pentoxifylline for 4 weeks after 1 h of ischemic priapism. At the completion of a 4-week period, penile tissues were obtained. Before penile tissues were obtained, intracavernosal pressures measured with electrical field stimulation and smooth muscle collagen ratio were evaluated pathologically.
Results
Electrical field stimulation-induced intracavernosal relaxation decreased in group 2 compared with group 1 (p < 0.05). Electrical field stimulation-induced relaxation enhanced in the group 3, 4 and 5 compared to group 2 (p < 0.05). In group 2, the collagen density was significantly higher than group 1. Administration of pentoxifylline reduced the collagen density caused by ischemic priapism in groups 3, 4 and 5 compared with group 2.
Conclusion
The results of the present study showed that ischemic priapism caused damage in the penile tissues of rats, and treatment with pentoxifylline reduced the harmful effects of ischemic priapism.
Similar content being viewed by others
References
Papadopoulos I, Kelâmi A (1988) Priapus and priapism. From mythology to medicine. Urology 32:385–386
Lue TF (1998) Physiology of penile erection and pathophysiology of erectile dysfunction and priapism. In: Walsh P, Retik AB, Vaughan ED, Wein AJ (eds) Campbell’s Urology, vol 3, 7th edn. Saunders Company, Philadelphia, pp 1157–1174
Minardi D, Milanese G, Galosi AB, Donatelli G, Muzzonigro G (2004) Persistent priapism and histological modifications of the erectile tissue. Two case reports. Arch Ital Urol Androl 76:97–99
Zheng DC, Yao HJ, Zhang K, Xu MX, Chen Q, Chen YB, Cai ZK, Lu MJ, Wang Z (2013) Unsatisfactory outcomes of prolonged ischemic priapism without early surgical shunts: our clinical experience and a review of the literature. Asian J Androl 15:75–78
Tay YK, Spernat D, Rzetelski-West K, Appu S, Love C (2012) Acute management of priapism in men. BJU Int 109(Suppl 3):15–21
Merkus D, Visser M, Houweling B, Zhou Z, Nelson J, Duncker DJ (2013) Phosphodiesterase 5 inhibition-induced coronary vasodilation is reduced after myocardial infarction. Am J Physiol Heart Circ Physiol 304:1370–1381
Pyriochou A, Zhou Z, Koika V, Petrou C, Cordopatis P, Sessa WC, Papapetropoulos A (2007) The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway. J Cell Physiol 211:197–204
Salhiyyah K, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. Jan 18, 2012;1:CD005262. doi:10.1002/14651858.CD005262.pub2
Seifi B, Kadkhodaee M, Delavari F, Mikaeili S, Shams S, Ostad SN (2012) Pretreatment with pentoxifylline and N-acetylcysteine in liver ischemia reperfusion-induced renal injury. Ren Fail 34:610–615
Bruno Rde B, Marques TF, Batista TM, Lima JC, de Arruda KG, Lima PF, Santos Nda S, Cunha GM, Vitor HV, Viana GS (2009) Pentoxifylline treatment improves neurological and neurochemical deficits in rats subjected to transient brain ischemia. Brain Res 1260:55–64
Sanli O, Armagan A, Kandirali E, Ozerman B, Ahmedov I, Solakoglu S, Nurten A, Tunç M, Uysal V, Kadioglu A (2004) TGF-beta1 neutralizing antibodies decrease the fibrotic effects of ischemic priapism. Int J Impot Res 16:492–497
Roghmann F, Becker A, Sammon JD, Ouerghi M, Sun M, Sukumar S, Djahangirian O, Zorn KC, Ghani KR, Gandaglia G, Menon M, Karakiewicz P, Noldus J, Trinh QD (2013) Incidence of priapism in emergency departments in the United States. J Urol 190:1275–1280
Kadioglu A, Sanli O, Celtik M, Cakan M, Taskapu H, Akman T (2006) Practical management of patients with priapism. EAU-EBU Updat Ser 4:150–160
Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP (2012) A review of outcomes of an intracavernosal injection therapy programme. BJU Int 110:1787–1791
Burnett AL, Bivalacqua TJ (2007) Priapism: current principles and practice. Urol Clin N Am 34:631–642
Sadeghi-Nejad H, Seftel AD (2002) The etiology, diagnosis, and treatment of priapism: review of the American Foundation for Urologic Disease Consensus Panel Report. Curr Urol Rep 3:492–498
Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R (2010) Priapism: pathogenesis, epidemiology, and management. J Sex Med 7:476–500
El-Bahnasawy MS, Dawood A, Farouk A (2002) Low-flow priapism: risk factors for erectile dysfunction. BJU Int 89:285–290
Kovac JR, Mak SK, Garcia MM, Lue TF (2013) A pathophysiology-based approach to the management of early priapism. Asian J Androl 15:20–26
Gottsch HP, Berger RE, Yang CC (2012) Priapism: comorbid factors and treatment outcomes in a contemporary series. Adv Urol 2012:672624
Hinman F (1914) Priapism: report of cases and a clinical study of the literature with reference to its pathogenesis and surgical treatment. Ann Surg 60:689–716
Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N (2002) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136:515–522
Fries R, Shariat K, Von WH, Bohm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985
Sharma R (2007) Novel phosphodiesterase-5 inhibitors: current indications and future directions. Indian J Med Sci 61:667–679
Liu Y, Shakur Y, Kambayashi J (2011) Phosphodiesterases as targets for intermittent claudication. Handb Exp Pharmacol 204:211–236
Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA, Scogin JT, Strandness DE (1982) Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 104:66–72
Strano A, Davi G, Avellone G, Novo S, Pinto A (1984) Double blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 35:459–466
Ladurner G, Kalvach P, Moessler H (2005) Cerebrolysin study group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J Neural Transm 112:415–428
Toda K, Kumagai N, Kaneko F, Tsunematsu S, Tsuchimoto K, Saito H, Hibi T (2009) Pentoxifylline prevents pig serum-induced rat liver fibrosis by inhibiting interleukin-6 production. J Gastroenterol Hepatol 24:860–865
Ng YY, Chen YM, Tsai TJ, Lan XR, Yang WC, Lan HY (2009) Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats. Am J Nephrol 29:43–53
Hung KY, Huang JW, Chiang CK, Tsai TJ (2008) Preservation of peritoneal morphology and function by pentoxifylline in a rat model of peritoneal dialysis: molecular studies. Nephrol Dial Transpl 23:3831–3840
Flechner L, Breyer BN, Eisenberg ML, Lue TF (2011) Pentoxifylline treatment and penile calcifications in men with Peyronie’s disease. Asian J Androl 13:322–325
Lin G, Shindel AW, Banie L (2010) Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1. J Sex Med 7:1787–1797
Albersen M, Fandel TM, Zhang H, Banie L, Lin G, De Ridder D, Lin CS, Lue TF (2011) Pentoxifylline promotes recovery of erectile function in a rat model of postprostatectomy erectile dysfunction. Eur Urol 59:286–296
Nasiri-Toosi Z, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M (2013) A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity. Eur J Clin Pharmacol 69:1057–1073
Abo-Salem OM (2013) Uroprotective effect of pentoxifylline in cyclophosphamide-induced hemorrhagic cystitis in rats. J Biochem Mol Toxicol 27:343–350
Archer SL, Roudebush WE (2013) Enhancement of sperm motility using pentoxifylline and platelet-activating factor. Methods Mol Biol 927:241–245
Savaş C, Dindar H, Aras T, Yücesan S (2002) Pentoxifylline improves blood flow to both testes in testicular torsion. Int Urol Nephrol 33:81–85
Tzeng YS, Tang SH, Meng E, Lin TF, Sun GH (2004) Ischemic glans penis after circumcision. Asian J Androl 6:161–163
Lin SL, Chen RH, Chen YM, Chiang WC, Lai CF, Wu KD, Tsai TJ (2005) Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol 16:2702–2713
Evliyaoğlu Y, Kayrin L, Kaya B (1997) Effect of pentoxifylline on veno-occlusive priapism-induced corporeal tissue lipid peroxidation in a rat model. Urol Res 25:143–147
Rajfer J, Gore JL, Kaufman J, Gonzalez-Cadavid N (2006) Case report: avoidance of palpable corporal fibrosis due to priapism with upregulators of nitric oxide. J Sex Med 3:173–176
Conflict of interest
No conflict of interest was declared by the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Erdemir, F., Firat, F., Markoc, F. et al. The effect of pentoxifylline on penile cavernosal tissues in ischemic priapism-induced rat model. Int Urol Nephrol 46, 1961–1967 (2014). https://doi.org/10.1007/s11255-014-0769-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-014-0769-z